HERPUD2

Across TCGA pan-cancer cohorts, HERPUD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HERPUD2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HERPUD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HERPUD2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

HNSC, GBM, and LUAD are the cancer types where HERPUD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.403	0.834	.038	4	view →
GBM	DFS	Median	All	0.466	0.276	.035	3	view →
LUAD	OS	Median	II,III,IV	1.000	0.845	.015	1	view →
LSCC	DFS	Quartile	All	0.821	0.437	.048	1	view →
PDAC	OS	Median	All	0.787	0.921	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HERPUD2–HNSC (DFS)

Open the HNSC breakdown →